A head-to-head comparison of adalimumab and vedolizumab for the treatment of ulcerative colitis finds vedolizumab is…
Read more
The first head-to-head trial of two biologics for psoriatic arthritis suggests that, while adalimumab and ixekizumab are…
Read more
Patients with moderate to severe ulcerative colitis are more likely to achieve clinical remission and a range of other…
Read more
The interleukin (IL-4) and IL-13 inhibitor dupilumab is an effective treatment for patients with severe chronic…
Read more
About one in three patients with axial spondyloarthritis are likely to achieve inactive disease six months into therapy with…
Read more
The combination of methotrexate with a biologic provides better outcomes than methotrexate monotherapy in adults with early…
Read more
The way physicians are classifying some rheumatoid arthritis patients as ‘non-responders’ to anti-TNFs suggests there is…
Read more